CLC bio collaborating with Apple

CLC bio has just been accepted as an official Apple Proprietary Solution Provider.

This means the company is capable of delivering full-service bioinformatics solutions to customers, with everything ranging from the newest Mac computers to CLC bio's high-performance computing devices and intuitive bioinformatics software.

Bjarne Knudsen, chief scientific officer at CLC bio, states: "We see this collaboration with Apple as a big recognition of what we have achieved over the past years.

"We are now going to focus even more on developing significant functionalities especially for our Universal Binaries software, as well as our high-performance computing products, which runs exceptionally well on Apple's Intel-based Macs.

"We believe that our customers will benefit remarkably from us sharing knowledge between the developer-teams in each company".

Arne Materna, researcher in the department of civil and environmental engineering at MIT states: "When I initially decided to work with CLC Gene Workbench this was because the software is an excellent and truly comprehensive bundle of applications, united under one easy-to-use platform.

"The main advantage in changing bioinformatics platform to CLC bio has been their high level of direct and uncomplicated customer service, their frequent product updates basing on user feedback, and their continuous commitment to providing up-to-date bioinformatics software to the newest Apple computers - a commitment that now materializes even stronger with CLC bio's new collaboration with Apple.

"We're focusing hard on delivering the best possible solutions to our customers and regard the Mac OS X version 10.4 (Tiger) and the upcoming Mac OS X version 10.5 (Leopard) as premier operating systems to support.

"This means our customers are always ensured their software can run on the latest version of the Mac OS X operating system, unlike other large competitors in the field of desktop-based bioinformatics".